Performance of RGNX Regenxbio | -33.7% in 12m
Compare RGNX with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Regenxbio with its related Sector/Index XBI
Performance Duell RGNX vs XBI
| TimeFrame | RGNX | XBI |
|---|---|---|
| 1 Week | -6.06% | -4.68% |
| 1 Month | -9.54% | 2.20% |
| 3 Months | -16.6% | 4.12% |
| 6 Months | -52.2% | -3.48% |
| 12 Months | -33.7% | 22.61% |
| YTD | -37.4% | 7.10% |
| Rel. Perf. 1m | -1.22 | |
| Rel. Perf. 3m | -4.83 | |
| Rel. Perf. 6m | -6.80 | |
| Rel. Perf. 12m | -6.80 | |
| Spearman 1m | -0.49 | 0.47 |
| Spearman 3m | -0.19 | 0.70 |
Is Regenxbio a good stock to buy?
No, based on ValueRay Fundamental Analyses, Regenxbio (NASDAQ:RGNX) is currently (September 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -61.58 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RGNX as of September 2024 is 8.63. This means that RGNX is currently overvalued and has a potential downside of -24.83% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RGNX as of September 2024 is 8.63. This means that RGNX is currently overvalued and has a potential downside of -24.83% (Sold with Premium).
Is RGNX a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: RGNX is performing better - Values below 0%: RGNX is underperforming
Compare RGNX with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -1.92% | -13.03% | -58.85% | -55.86% |
| US NASDAQ 100 | QQQ | -0.27% | -11.62% | -54.72% | -53.53% |
| US Dow Jones Industrial 30 | DIA | -3.24% | -13.34% | -57.47% | -52.18% |
| German DAX 40 | DBXD | -2.82% | -14.94% | -55.00% | -48.28% |
| UK FTSE 100 | ISFU | -3.81% | -15.81% | -64.49% | -51.84% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.38% | -7.23% | -45.90% | -22.77% |
| Hongkong Hang Seng | HSI | -3.84% | -14.31% | -52.68% | -27.84% |
| Japan Nikkei 225 | EXX7 | 1.06% | -15.22% | -42.04% | -39.54% |
| India NIFTY 50 | INDA | -3.96% | -12.15% | -60.61% | -57.99% |
| Brasil Bovespa | EWZ | -4.35% | -16.42% | -43.66% | -33.92% |
RGNX Regenxbio vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -1.99% | -10.13% | -59.54% | -58.20% |
| Consumer Discretionary | XLY | -3.54% | -14.93% | -54.16% | -39.77% |
| Consumer Staples | XLP | -6.64% | -15.61% | -63.99% | -51.83% |
| Energy | XLE | -0.29% | -8.42% | -52.49% | -31.54% |
| Financial | XLF | -2.89% | -16.26% | -62.07% | -64.42% |
| Health Care | XLV | -3.99% | -13.91% | -58.40% | -51.33% |
| Industrial | XLI | -1.82% | -12.69% | -56.38% | -54.75% |
| Materials | XLB | -1.40% | -11.13% | -54.27% | -45.33% |
| Real Estate | XLRE | -6.24% | -14.55% | -63.94% | -57.05% |
| Technology | XLK | 1.39% | -11.20% | -50.92% | -52.00% |
| Utilities | XLU | -5.56% | -13.71% | -74.29% | -57.44% |
| Aerospace & Defense | XAR | -0.85% | -13.54% | -56.64% | -60.02% |
| Biotech | XBI | -1.38% | -11.74% | -48.69% | -56.29% |
| Homebuilder | XHB | -1.66% | -12.96% | -60.01% | -71.28% |
| Retail | XRT | -1.08% | -9.03% | -48.92% | -52.33% |
Does Regenxbio outperform its market, is RGNX a Sector Leader?
No, over the last 12 months Regenxbio (RGNX) made -33.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 22.61%.
Over the last 3 months RGNX made -16.57%, while XBI made 4.12%.
No, over the last 12 months Regenxbio (RGNX) made -33.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 22.61%.
Over the last 3 months RGNX made -16.57%, while XBI made 4.12%.
| Period | RGNX | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -9.54% | 2.20% | 3.49% |
| 3 Months | -16.57% | 4.12% | 1.39% |
| 12 Months | -33.68% | 22.61% | 22.18% |